Personalized ceftobiprole dosing for older adults
Part of Infections clinical trials.
This study tests whether tailoring the dose of the antibiotic ceftobiprole based on your individual body and kidney function helps treat infections more safely and effectively in older adults.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 60 years old.
- You will be receiving ceftobiprole (an antibiotic) for more than 5 days.
- You cannot have used ceftobiprole in the month before the study starts.
- You must not be on dialysis or have severe kidney problems (like kidney failure, a single kidney, or a kidney transplant).
- Your body mass index (BMI) must be less than 30.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether giving the antibiotic ceftazidime-avibactam in a personalized way, based on your body's ability to process the drug, works better for adults 60 and older with serious infections. The goal is to improve treatment outcomes and reduce side effects.
This trial tests a new antibiotic called ceftibuten-ledaborbactam in healthy volunteers to see if it is safe and how the body processes it. You may join if you are a healthy adult and do not have allergies to certain antibiotics.
This trial tests whether giving the antibiotic ceftazidime earlier and in a more personalized way helps clear infections faster in ICU patients. It may improve recovery by making sure the right dose reaches your body at the right time.
This trial tests whether measuring drug levels in the blood can help doctors give the right dose of ceftazidime-avibactam (an antibiotic) to patients with hard-to-treat infections in the ICU, potentially improving treatment outcomes and reducing side effects.
This study tests two ways of giving the antibiotic ceftazidime/avibactam (as a continuous drip or as intermittent shots) to patients in the intensive care unit with severe infections. The goal is to see which method works better or is safer for critically ill patients.
This trial tests whether a newer antibiotic (ceftolozane/tazobactam) works as well as the standard drug (meropenem) for treating fever and low white blood cell counts in people who carry or are at risk for a certain type of resistant bacteria (ESBL). If you are colonized with ESBL or have recently used certain antibiotics, you may be eligible.
Hear when a new Ceftobiprole trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.